Agila Specialties Pharma Corporation, Canada, which is part of the injectable drug division of Strides Arcolab, a publicly-held generic drug manufacturer, has formed a joint venture with Jamp Pharma, a Canadian generic drug company, to introduce a variety of quality injectable generic drugs in Canada.
This sales and marketing joint venture will operate under the name ‘Agila-Jamp Canada Inc’ in which Agila will hold a 70 per cent stake and the remaining by Jamp Pharma. The JV will be headquartered in Boucherville, Québec. Agila-Jamp will launch around 40 products in the next two years.
Many of these products have already been approved by Health Canada and will be immediately launched through local hospitals and pharmacists. The existing sales force at Jamp Pharma will be responsible to introduce the entire Agila-Jamp product portfolio.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
